Tau protein

Tau protein
National Center for Biotechnology Information, U.S. National Library of Medicine · Public domain · source
Name	Tau protein
Uniprot	P10636
Organism	Homo sapiens
Gene	MAPT
Length	441 aa (canonical human isoform)
Location	Brain, axon, neuron

Tau protein Tau protein is a microtubule-associated protein encoded by the MAPT gene that stabilizes neuronal cytoskeleton and modulates axonal transport. Widely studied in neuroscience and neuropathology, tau is central to research at institutions such as National Institutes of Health, Alzheimer's Disease Research Center, and laboratories collaborating with Cold Spring Harbor Laboratory and University College London. Its dysregulation underlies major neurodegenerative disorders that attract attention from agencies like the World Health Organization and foundations such as the Alzheimer's Association.

Structure and Isoforms

Tau comprises an intrinsically disordered N-terminal projection domain, a proline-rich region, and a C-terminal microtubule-binding domain containing three or four repeat motifs. Alternative splicing of exons in the MAPT locus generates six primary adult human isoforms (ranging from 352 to 441 amino acids) that differ by inclusion of N-terminal inserts and the presence of three-repeat (3R) versus four-repeat (4R) microtubule-binding repeats. Structural characterization has involved techniques developed at European Molecular Biology Laboratory, Max Planck Institute for Biochemistry, and cryo-electron microscopy efforts exemplified by work at MRC Laboratory of Molecular Biology and Harvard Medical School. Comparative genomics across mammals, primates, and model organisms such as Mus musculus and Drosophila melanogaster reveal conserved motifs and species-specific splicing patterns.

Physiological Function

Physiologically, tau binds to and stabilizes microtubules in axons, regulating microtubule dynamics central to vesicle and organelle transport mediated by motor proteins like kinesin and dynein. Tau influences neuronal polarity, synaptic function, and plasticity studied in experimental systems at Stanford University and Massachusetts Institute of Technology. In development and adult plasticity, tau interactions with scaffold proteins, signaling complexes, and membrane-associated factors coordinate with pathways investigated at Salk Institute and Johns Hopkins University. Its regional expression varies across brain areas such as the hippocampus, cerebral cortex, and basal ganglia, aligning with vulnerability patterns observed in clinical neurology centers including Mayo Clinic.

Post-translational Modifications and Regulation

Tau undergoes extensive post-translational modifications (PTMs) including phosphorylation, acetylation, ubiquitination, methylation, glycosylation, and truncation. Proline-directed kinases such as CDK5 and GSK3β, studied at University of Cambridge and Yale University, phosphorylate tau at multiple serine/threonine sites, reducing microtubule affinity. Acetylation by enzymes linked to chromatin biology at Columbia University and deacetylases like SIRT1 alter tau turnover and aggregation propensity. The ubiquitin–proteasome system and autophagy pathways characterized at Rockefeller University and Karolinska Institutet mediate tau clearance. Genetic variants in MAPT haplotypes associated with susceptibility to tauopathies were mapped through consortia including International Parkinson Disease Genomics Consortium and large cohort studies at University of California, San Francisco.

Role in Neurodegenerative Diseases

Abnormal tau accumulation defines a spectrum of tauopathies including Alzheimer's disease, Progressive supranuclear palsy, Corticobasal degeneration, Frontotemporal dementia, and chronic traumatic encephalopathy. In Alzheimer's disease, paired helical filaments composed of hyperphosphorylated tau correlate with cognitive decline measured in longitudinal studies at Framingham Heart Study cohorts and neuroimaging trials run by National Institute on Aging. Clinicopathological correlations from neuropathology centers such as Mayo Clinic and University of Pennsylvania link regional tau pathology to clinical phenotypes. Familial frontotemporal dementia cases with MAPT mutations reported by teams at University College London and University of California, San Diego established causal relationships between sequence changes and altered microtubule binding or aggregation.

Mechanisms of Tau Aggregation and Propagation

Tau aggregation proceeds from soluble monomers to oligomers, protofibrils, and ordered amyloid fibrils, with filament structures resolved by cryo-EM in studies led by groups at MRC Laboratory of Molecular Biology and University of Cambridge. Post-translationally modified tau species, seeding activity, and templated misfolding underlie cell-to-cell propagation phenomena demonstrated in models using techniques developed at The Scripps Research Institute and University of Pennsylvania. Extracellular release, uptake via endocytosis, and trans-synaptic transfer engage pathways investigated at Columbia University and Washington University in St. Louis. Strain-like conformers producing distinct neuropathological patterns have been characterized by collaborative networks including laboratories at University of Texas Southwestern Medical Center.

Diagnostic and Therapeutic Approaches

Diagnostic advances include tau-targeted positron emission tomography ligands validated in multicenter trials coordinated by Alzheimer's Disease Neuroimaging Initiative and biomarker assays for cerebrospinal fluid and plasma tau developed by consortia such as European Prevention of Alzheimer's Dementia (EPAD). Therapeutic strategies under clinical investigation encompass small-molecule kinase inhibitors from pharmaceutical collaborators like Pfizer and Roche, immunotherapies (monoclonal antibodies and vaccines) advanced by biotech companies including Biogen and Eli Lilly and Company, antisense oligonucleotides pursued at Ionis Pharmaceuticals, and agents modulating proteostasis pathways studied in academic–industry partnerships at Broad Institute. Preclinical research leveraging models from Jackson Laboratory and clinical trial networks such as Global Alzheimer Platform continues to define target engagement, safety, and efficacy endpoints.

Category:Proteins Category:Neuroscience Category:Neurodegenerative diseases